Danaher Corporation – Consensus ‘buy’ rating and 32.7% Upside Potential

Broker Ratings

Danaher Corporation which can be found using ticker (DHR) now have 25 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $310.00 and $240.00 calculating the average target price we see $268.26. Given that the stocks previous close was at $202.18 and the analysts are correct then we can expect a percentage increase in value of 32.7%. The day 50 moving average is $230.23 and the 200 day moving average is $251.69. The market capitalization for the company is 146.40B. The price for the stock stands currently at: $203.59 USD

The potential market cap would be $194,249,647,259 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 38.49, revenue per share of $32.29 and a 3.86% return on assets.

Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. The Company’s segments include Biotechnology, which includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables and services; Life Sciences segment, which offers a range of instruments and consumables that are primarily used by customers to study the basic building blocks of life, including genes, proteins, metabolites, and cells, to understand the causes of disease, identify new therapies, and test and manufacture new drugs and vaccines; Diagnostics segment that offers clinical instruments, reagents, consumables, software, and services that hospitals, physicians’ offices, reference laboratories, and other critical care settings use to diagnose disease, and Environmental & Applied Solutions segment, which offers products and services that help protect precious resources and keep global food and water supplies safe.

Share on:
Find more news, interviews, share price & company profile here for:

      Search

      Search